JP2024534080A5 - - Google Patents
Info
- Publication number
- JP2024534080A5 JP2024534080A5 JP2024510252A JP2024510252A JP2024534080A5 JP 2024534080 A5 JP2024534080 A5 JP 2024534080A5 JP 2024510252 A JP2024510252 A JP 2024510252A JP 2024510252 A JP2024510252 A JP 2024510252A JP 2024534080 A5 JP2024534080 A5 JP 2024534080A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163233966P | 2021-08-17 | 2021-08-17 | |
| US63/233,966 | 2021-08-17 | ||
| PCT/US2022/040485 WO2023023070A2 (en) | 2021-08-17 | 2022-08-16 | Inducible il-2 and pd-1/pd-l1 combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534080A JP2024534080A (ja) | 2024-09-18 |
| JP2024534080A5 true JP2024534080A5 (https=) | 2025-08-25 |
| JPWO2023023070A5 JPWO2023023070A5 (https=) | 2025-08-25 |
Family
ID=85239704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024510252A Pending JP2024534080A (ja) | 2021-08-17 | 2022-08-16 | 誘導性ｉｌ－２及びｐｄ－１／ｐｄ－ｌ１の併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240216470A1 (https=) |
| EP (1) | EP4387650A4 (https=) |
| JP (1) | JP2024534080A (https=) |
| KR (1) | KR20240051178A (https=) |
| CN (1) | CN118103058A (https=) |
| AU (1) | AU2022331262A1 (https=) |
| CA (1) | CA3229021A1 (https=) |
| WO (1) | WO2023023070A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3854805A4 (en) | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| WO2025140535A1 (zh) * | 2023-12-28 | 2025-07-03 | 福佑泰生物制药（新加坡）公司 | Pd-1/il-2r双特异性抗体融合蛋白及其用途和使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6720075B2 (ja) * | 2013-05-31 | 2020-07-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌のための併用療法 |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
-
2022
- 2022-08-16 CA CA3229021A patent/CA3229021A1/en active Pending
- 2022-08-16 KR KR1020247008939A patent/KR20240051178A/ko active Pending
- 2022-08-16 JP JP2024510252A patent/JP2024534080A/ja active Pending
- 2022-08-16 AU AU2022331262A patent/AU2022331262A1/en active Pending
- 2022-08-16 WO PCT/US2022/040485 patent/WO2023023070A2/en not_active Ceased
- 2022-08-16 EP EP22859050.1A patent/EP4387650A4/en active Pending
- 2022-08-16 CN CN202280069956.XA patent/CN118103058A/zh active Pending
-
2024
- 2024-02-13 US US18/440,775 patent/US20240216470A1/en active Pending